WallStSmart

Coherent Inc (COHR)vsMesa Laboratories Inc (MLAB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Coherent Inc generates 2443% more annual revenue ($6.29B vs $247.54M). COHR leads profitability with a 4.7% profit margin vs 1.5%. MLAB trades at a lower P/E of 126.8x. COHR earns a higher WallStSmart Score of 52/100 (C-).

COHR

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 4.5Value: 4.7Quality: 6.3
Piotroski: 5/9Altman Z: 1.53

MLAB

Hold

38

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 3.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COHRSignificantly Overvalued (-373.2%)

Margin of Safety

-373.2%

Fair Value

$47.27

Current Price

$272.04

$224.77 premium

UndervaluedFair: $47.27Overvalued
MLABSignificantly Overvalued (-1964.0%)

Margin of Safety

-1964.0%

Fair Value

$4.42

Current Price

$83.60

$79.18 premium

UndervaluedFair: $4.42Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COHR4 strengths · Avg: 8.8/10
EPS GrowthGrowth
73.0%10/10

Earnings expanding 73.0% YoY

Market CapQuality
$51.06B9/10

Large-cap with strong market position

PEG RatioValuation
0.928/10

Growing faster than its price suggests

Revenue GrowthGrowth
17.5%8/10

17.5% revenue growth

MLAB1 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

COHR4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.534/10

Distress zone — elevated risk

Return on EquityProfitability
3.2%3/10

ROE of 3.2% — below average capital efficiency

Profit MarginProfitability
4.7%3/10

4.7% margin — thin

P/E RatioValuation
269.6x2/10

Premium valuation, high expectations priced in

MLAB4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

Market CapQuality
$455.25M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.2%3/10

ROE of 2.2% — below average capital efficiency

Profit MarginProfitability
1.5%3/10

1.5% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : COHR

The strongest argument for COHR centers on EPS Growth, Market Cap, PEG Ratio. Revenue growth of 17.5% demonstrates continued momentum. PEG of 0.92 suggests the stock is reasonably priced for its growth.

Bull Case : MLAB

The strongest argument for MLAB centers on Price/Book.

Bear Case : COHR

The primary concerns for COHR are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 269.6x leaves little room for execution misses. Thin 4.7% margins leave little buffer for downturns.

Bear Case : MLAB

The primary concerns for MLAB are Revenue Growth, Market Cap, Return on Equity. A P/E of 126.8x leaves little room for execution misses. Thin 1.5% margins leave little buffer for downturns.

Key Dynamics to Monitor

COHR profiles as a growth stock while MLAB is a value play — different risk/reward profiles.

COHR carries more volatility with a beta of 1.91 — expect wider price swings.

COHR is growing revenue faster at 17.5% — sustainability is the question.

MLAB generates stronger free cash flow (18M), providing more financial flexibility.

Bottom Line

COHR scores higher overall (52/100 vs 38/100) and 17.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coherent Inc

TECHNOLOGY · SCIENTIFIC & TECHNICAL INSTRUMENTS · USA

Coherent, Inc. provides lasers, laser-based technologies, and laser-based system solutions for a variety of scientific, commercial, and industrial research applications. The company is headquartered in Santa Clara, California.

Mesa Laboratories Inc

TECHNOLOGY · SCIENTIFIC & TECHNICAL INSTRUMENTS · USA

Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company is headquartered in Lakewood, Colorado.

Want to dig deeper into these stocks?